Supply of Zovirax Ophthalmic Ointment (aciclovir 3%) resumes
Resumed supply of Zovirax Ophthalmic Ointment confirmed following a global supply shortage.
Read more - Supply of Zovirax Ophthalmic Ointment (aciclovir 3%) resumes Read more
Press releases
These press releases are intended for business journalists and analysts/investors
Product Recall - Children's Panadol
We are recalling two batches of Children’s Panadol 5-12 Suspension Strawberry (200mL) and one batch of Children’s Panadol 5-12 Suspension Orange (200mL)
GSK Australia Reports 2015 results to ASIC
GlaxoSmithKline (GSK) Australia has reported its 2015 results to the Australian Securities and Investment Commission (ASIC) for its pharmaceuticals and vaccines business, as well as GSK Consumer Healthcare (a joint venture with Novartis) and ViiV (a joint venture with Pfizer and Shionogi focused on HIV).
Read more - GSK Australia Reports 2015 results to ASIC Read more
GSK discloses payments to Australian healthcare professionals in 2015
In 2015, GSK Australia made payments totalling $3.6 million to healthcare professionals (HCPs) and health-related organisations (HCOs) for grants, sponsorships and consultancy fees related to chairing and speaking at meetings, assistance with training and participation in advisory boards.
Read more - GSK discloses payments to Australian healthcare professionals in 2015 Read more
Supply of Bactroban products
GSK advises of a temporary disruption to the supply of Bactroban products
Whooping cough vaccines update
GSK responds to Tropical Cyclone Winston in Fiji
GSK has responded to the state of emergency declared in Fiji by providing funding and urgent supplies of medicine.
Read more - GSK responds to Tropical Cyclone Winston in Fiji Read more
GSK supports National Immunisation Program (NIP) with additional whooping cough protection via an 18-month dose on the NIP
GSK Australia is proud to be partnering with the Australian Government to re-introduce a diphtheria, tetanus, acellular pertussis (DTPa) vaccine on the National Immunisation Program for children at 18-months of age.
Australia leads the world in body pain blues
New research conducted on behalf of Voltaren and GSK Consumer Healthcare shows that 97 percent of Australians suffer from body aches, with a massive two thirds (68%) experiencing it at least weekly, higher than the other 13 countries included in the survey. Findings show pain impacts our social life, love life, performance at work and ability to parent.
Read more - Australia leads the world in body pain blues Read more
GSK establishes Immunology Network to collaborate with academic research scientists
GSK has launched a new immunology research collaboration model – the Immunology Catalyst sabbatical program – designed to embed academic scientists in GSK laboratories with the goal to broaden scientific insight and drive major breakthroughs in applied immunology.
Australian Professor John Hamilton from the University of Melbourne was the first academic to join the program.
